Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $39.03M (cash outflow) rose 500.8% year over year, ahead of the +141.3% change in trailing-twelve-month net income. Sequentially, it rose 273.6% from the prior quarter. Over 3 fiscal years it compounded at -19.7% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$72.34M (+58.6%) for the fiscal year ending Dec 2026, a step up from the +26.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.03M+273.6% QoQ
- Last fiscal yearDec 2025
- -$45.62M+26.1% YoY
- LTMMar 2026
- -$78.15M+141.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +500.8% | +58.4% | -442.5 pp |
| 1 year | +26.1% | +58.6% | +32.5 pp |
| 3-year CAGR | -19.7% | +14.1% | +33.7 pp |
| 5-year CAGR | +0.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (45.62M) USD
- Year-over-year change
- -26.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.62M) | -26.1% |
| FY2024 | 2024-12-31 | (36.18M) | +69.0% |
| FY2023 | 2023-12-31 | (116.54M) | -32.5% |
| FY2022 | 2022-12-31 | (87.97M) | -154.9% |
| FY2021 | 2021-12-31 | (34.51M) | — |
Net Income vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 net income of $78.15M is the 8th largest of the 11 companies compared; the peer median is $112.8M.
- Its year-over-year change of +141.3% is the 3rd highest of 11, against a peer median of +17.1%.
- Over three fiscal years its annual growth of -19.7% compares with a peer median of +13.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $239.55M | +441.4% | — | 110.0% | |
| LTM Mar 2026 | $173.76M | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $169.52M | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $166.12M | -770.3% | +15.0% | 2895.1% | |
| LTM Mar 2026 | $116.64M | +37.7% | +37.1% | 319.6% | |
| LTM Mar 2026 | $108.95M | -56.6% | -10.1% | 281.6% | |
| LTM Mar 2026 | $97.59M | +25.7% | +50.6% | 4840.8% | |
| LTM Mar 2026 | $78.15M | +141.3% | -19.7% | — | |
| LTM Mar 2026 | $66.14M | +249.7% | — | 454.9% | |
| LTM Mar 2026 | $51.99M | +12.6% | +8.9% | — | |
| LTM Mar 2026 | $24.38M | -35.9% | +2396.3% | 10.7% | |
| Peer median (excluding ELDN) | $112.8M | +17.1% | +13.0% | 319.6% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| Deferred Income Tax | (2.35M) | 0 | 0 | 431K | 5K |
| Stock-Based Compensation | 7.9M | 8.15M | 6.55M | 13.12M | 10.45M |
| Change in Working Capital | (152K) | 2.37M | (4.92M) | 8.71M | 7.65M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.14M | 2.08M | (2.6M) | 7.75M | 6.72M |
| Other Working Capital | (2.3M) | 287K | (2.32M) | 959K | 928K |
| Other Non-Cash Items | 0 | 48.65M | 75.01M | (33.71M) | (35.15M) |
| Operating Cash Flow | (28.91M) | (28.42M) | (39.53M) | (47.27M) | (62.34M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (78.29M) | (156.13M) | (161.13M) |
| Sales of Investments | 0 | 0 | 33M | 85.82M | 171.93M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | (45.29M) | (70.31M) | 10.79M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (449K) | 0 | 33.02M | 133.31M | 53.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 215K | 0 |
| Financing Cash Flow | (449K) | 0 | 33.02M | 133.52M | 53.81M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.36M) | (28.42M) | (51.8M) | 15.94M | 2.26M |
| Free Cash Flow | (28.91M) | (28.42M) | (39.53M) | (47.27M) | (62.34M) |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.